Results 191 to 200 of about 5,486,230 (294)

The Hidden Cost of Delay: Post-Pandemic Evolution of Advanced Ovarian Cancer Profiles. [PDF]

Medicina (Kaunas)
Petrusan AM, Feier CVI, Muntean C, Gaborean V, Petrusan AS, Nicoara D, Puscas EM, Ignat FL, Achimas-Cadariu P.   +8 more
europepmc   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). [PDF]

J Natl Cancer Inst
Joly F, Anota A, Chabaud S, Cropet C, Priou F, Harter P, Pignata S, Palacio I, Petru E, Kobayashi H, Vergote I, Parma G, Mäenpää J, Raymond E, Ataseven B, Pisano C, Lainez N, Tsibulak I, Yonemori K, Vuylsteke P, Lapresa MT, Mirza MR, Bouchaert P, Buderath P, Lorusso D, Herrero A, Eberst L, Burges A, Scambia G, Ortega E, Guillemet C, Pujade-Lauraine E, Kurtz JE, Ray-Coquard I.   +33 more
europepmc   +1 more source

Innovation of plant‐derived extracellular vesicles and interdisciplinary research: From discovery to biomedical applications

BMEMat, EarlyView.
Plant‐derived extracellular vesicles offer numerous advantages and are regarded as highly promising candidates in the field of biomedicine. Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells.
Zilin Li, Yi Wei, Ben Hu, Yafang Song, Xiaojia Chen, Nik Ahmad Nizam Nik Malek, Tongkai Chen   +6 more
wiley   +1 more source

Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center. [PDF]

Front Oncol
Schwörer I, Huwer S, Rautenberg B, Neubauer J, Juhasz-Böss I, Jung L.   +5 more
europepmc   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer. [PDF]

Cancer Med
Li Y, Yuan L, Lou G, Cai H, Li Y, Li F, Wang L, Long X, Gong Y, Zhu C, Li L, Xu J, Zhou Q.   +12 more
europepmc   +1 more source

Screening of bispecific antibodies during single cell cloning of recombinant Chinese hamster ovary cell lines to improve titer and product quality

Biotechnology Progress, EarlyView.
Abstract Development of therapeutic bispecific antibodies (BsAbs) poses significant manufacturability challenges associated with correct chain pairing and an increased diversity of impurities. Here we address this with a product quality assessment during cell line development (CLD), forgoing the need for genetic characterization during cell line ...
Molly Robinson, Jessica Willmott, Holly Corrigall, Daniela Lega, Joseph Stirling, Vithiya Vimalraj, Mitul Patel, Robyn Emmins   +7 more
wiley   +1 more source

Predictive value of the KELIM in neoadjuvant treatment for patients with advanced ovarian cancer. [PDF]

Front Oncol
Wang Y, Yu Y, Yuan H, Wang L, Bian P, Yang Y, Wang J.   +6 more
europepmc   +1 more source

Flocculation using selected cationic polymers reduces high‐risk host cell proteins in monoclonal antibody processes already during primary recovery

Biotechnology Progress, EarlyView.
Flocculation using cationic polymers leads to the creation of large floc complexes. Negative charged species like cells, cell debris, and negatively charged host cell impurities like host cell DNA and host cell proteins are trapped within the complex while the positively charged monoclonal antibody stays in solution.
Anna‐Carina Frank, Daniel Komuczki, Gregor Stitz, Timon Kalchmayr, Clemens Grünwald‐Gruber, Clara Hofmann, Natalie Deiringer, Christine Rösch, Peter Satzer, Rainer Hahn   +9 more
wiley   +1 more source